ALA 5.41% 19.5¢ arovella therapeutics limited

Ann: New Analyst Report, page-28

  1. 3,684 Posts.
    lightbulb Created with Sketch. 658
    Regarding the timelines I'm told (and don't hold it against me)-
    Pfizer has confirmed a Q2 timeline regarding decisions,
    Zolpi Master is back moving (JS take not). For memory our man championing the deal went walkabout but has now returned,
    Some other good stuff going on with 001 and zolpi too. Hopefully something Q1 or early Q2... DYOR,
    Artimist .....DYOR
 
watchlist Created with Sketch. Add ALA (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.